CoChat
Sign Up
Cited by 85

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

L‐ornithine L‐aspartate in acute treatment of severe hepatic encephalopathy: A double‐blind randomized controlled trial

Jain, Arpan, Sharma, Barjesh Chander, Mahajan, Bhawna, Srivastava, Siddharth, Kumar, Ajay, Sachdeva, Sanjeev, Sonika, Ujjwal, Dalal, Ashok·2022·Hepatology
DOI 10.1002/hep.32255
Open this paper in CoChat — free account

Abstract

Background and Aims: Data on the use of intravenous L‐ornithine L‐aspartate (LOLA) in the treatment of overt HE (OHE) is limited. We evaluated the role of intravenous LOLA in patients of cirrhosis with OHE grade III–IV. Approach and Results: In a double‐blind randomized placebo‐controlled trial, 140 patients were randomized to a combination of LOLA, lactulose, and rifaximin (n = 70) or placebo, lactulose, and rifaximin (n = 70). LOLA was given as continuous intravenous infusion at a dose of 30 g over 24 h for 5 days. Ammonia levels, TNF‐α, ILs, and endotoxins were measured on days 0 and 5. The primary outcome was the improvement in the grade of HE at day 5. Higher rates of improvement in grade of HE (92.5% vs. 66%, p < 0.001), lower time to recovery (2.70 ± 0.46 vs. 3.00 ± 0.87 days, p = 0.03), and lower 28‐day mortality (16.4% vs. 41.8%, p = 0.001) were seen in the LOLA group as compared with placebo. Levels of inflammatory markers were reduced in both groups. Significantly higher reductions in levels of blood ammonia, IL‐6, and TNF‐α were seen in the LOLA group. Conclusions: Combination of LOLA with lactulose and rifaximin was more effective than only lactulose and rifaximin in improving grades of HE, recovery time from encephalopathy, with lower 28‐day mortality.

Overview

Integrity signals

Registry

Crossref · 10.1002/hep.32255

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. 2014, Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver, Hepatology, 60, 715, 10.1002/hep.27210 · DOI
  2. 2010, Mechanisms, diagnosis and management of hepatic encephalopathy, Nat Rev Gastroenterol Hepatol, 7, 515, 10.1038/nrgastro.2010.116 · DOI
  3. 2014, Hepatic encephalopathy is associated with significantly increased mortality among patients awaiting liver transplantation, Liver Transpl, 20, 1454, 10.1002/lt.23981 · DOI
  4. 2011, Prognostic assessment in patients with hepatic encephalopathy, Dis Markers, 31, 171, 10.1155/2011/832031 · DOI
  5. 2008, Incidence and prevalence of cirrhosis in the United Kingdom, 1992–2001: a general population‐based study, J Hepatol, 49, 732, 10.1016/j.jhep.2008.05.023 · DOI
  6. 1987, Ammonia: key factor in the pathogenesis of hepatic encephalopathy, Neurochem Pathol, 6, 1, 10.1007/BF02833598 · DOI
  7. 2008, Pathogenetic mechanisms of hepatic encephalopathy, Gut, 57, 1156, 10.1136/gut.2007.122176 · DOI
  8. 2018, L‐ornithine L‐aspartate in bouts of overt hepatic encephalopathy, Hepatology, 67, 700, 10.1002/hep.29410 · DOI · Paper page
  9. 2019, l‐ornithine l‐aspartate (LOLA) for hepatic encephalopathy in cirrhosis: results of randomized controlled trials and meta‐analyses, Drugs, 79, 31
  10. 2018, Efficacy of l‐ornithine l‐aspartate for the treatment of hepatic encephalopathy and hyperammonemia in cirrhosis: systematic review and meta‐analysis of randomized controlled trials, J Clin Exp Hepatol, 8, 301, 10.1016/j.jceh.2018.05.004 · DOI
  11. 2019, l‐ornithine l‐aspartate (LOLA) as a novel approach for therapy of non‐alcoholic fatty liver disease, Drugs, 79, 39
  12. 2014, Acute‐on‐chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014, Hepatol Int, 8, 453, 10.1007/s12072-014-9580-2 · DOI · Paper page
  13. 2013, Acute‐on‐chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis, Gastroenterology, 144, 1426, 10.1053/j.gastro.2013.02.042 · DOI
  14. 2008, L‐ornithine‐L‐aspartate infusion efficacy in hepatic encephalopathy, J Coll Physicians Surg‐Pak JCPSP, 18, 684
  15. 2017, Randomized controlled trial comparing lactulose plus albumin versus lactulose alone for treatment of hepatic encephalopathy, J Gastroenterol Hepatol, 32, 1234, 10.1111/jgh.13666 · DOI
  16. 2020, Beneficial effects of L‐ornithine L‐aspartate for prevention of overt hepatic encephalopathy in patients with cirrhosis: a systematic review with meta‐analysis, Metab Brain Dis, 35, 75, 10.1007/s11011-019-00463-8 · DOI
  17. 2019, Raised serum Interleukin‐6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathy, Aliment Pharmacol Ther, 50, 1112, 10.1111/apt.15515 · DOI
  18. 2019, Hepatic encephalopathy aggravated by systemic inflammation, Dig Dis, 37, 509, 10.1159/000500717 · DOI
  19. 2019, Hepatoprotection by L‐ornithine L‐aspartate in non‐alcoholic fatty liver disease, Dig Dis Basel Switz, 37, 63
  20. 2004, Serum levels of tumor necrosis factor‐alpha correlate with severity of hepatic encephalopathy due to chronic liver failure, Liver Int, 24, 110, 10.1111/j.1478-3231.2004.0894.x · DOI
  21. 2010, Admission levels and early changes in serum interleukin‐10 are predictive of poor outcome in acute liver failure and decompensated cirrhosis, Liver Int, 30, 733, 10.1111/j.1478-3231.2010.02219.x · DOI
  22. 2011, The relation between pathogenesis of liver cirrhosis, hepatic encephalopathy and serum cytokine levels: what is the role of tumor necrosis factor α?, Hepatogastroenterology, 58, 943
  23. 2000, High levels of serum interleukin‐10 and tumor necrosis factor‐alpha are associated with fatality in fulminant hepatitis, J Infect Dis, 182, 1103, 10.1086/315826 · DOI
  24. 2012, Serum endotoxin and inflammatory mediators in patients with cirrhosis and hepatic encephalopathy, Dig Liver Dis, 44, 1027, 10.1016/j.dld.2012.07.002 · DOI · Paper page
  25. 1996, Effects of tumor necrosis factor‐alpha and interleukin‐6 on fluid‐phase permeability and ammonia diffusion in CNS‐derived endothelial cells, J Investig Med, 44, 474
  26. 2004, Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis, J Hepatol, 40, 247, 10.1016/j.jhep.2003.10.016 · DOI
  27. 2011, Infection and systemic inflammation, not ammonia, are associated with grade 3/4 hepatic encephalopathy, but not mortality in cirrhosis, J Hepatol, 54, 640, 10.1016/j.jhep.2010.07.045 · DOI
  28. 2007, Role of ammonia and inflammation in minimal hepatic encephalopathy, Metab Brain Dis, 22, 125, 10.1007/s11011-006-9042-1 · DOI
  29. 2005, Effects of cytokines on microglial phenotypes and astroglial coupling in an inflammatory coculture model, Glia, 52, 85, 10.1002/glia.20223 · DOI
  30. 2007, Inflammation and hepatic encephalopathy: ibuprofen restores learning ability in rats with portacaval shunts, Hepatology, 46, 514, 10.1002/hep.21734 · DOI
  31. 2007, Model for end‐stage liver disease score and systemic inflammatory response are major prognostic factors in patients with cirrhosis and acute functional renal failure, Hepatology, 46, 1872, 10.1002/hep.21920 · DOI
  32. 2019, Prognostic role of ammonia in patients with cirrhosis, Hepatology, 70, 982, 10.1002/hep.30534 · DOI
  33. 2015, Hepatoselective nitric xxide (NO) donors, V‐PYRRO/NO and V‐PROLI/NO, in nonalcoholic fatty liver disease: a comparison of antisteatotic effects with the biotransformation and pharmacokinetics, Drug Metab Dispos, 43, 1028, 10.1124/dmd.115.063388 · DOI
  34. 2017, The brain‐muscle axis in minimal hepatic encephalopathy (MHE): a placebo‐controlled, longitudinal double‐blind trial with l‐ornithine l‐aspartate (LOLA): preliminary results, J Clin Exp Hepatol, 7, S5, 10.1016/j.jceh.2017.01.009 · DOI

Cited by

Sorted by citations

Metadata

Authors
Jain, A., Sharma, B. C., Mahajan, B., Srivastava, S., Kumar, A., Sachdeva, S., Sonika, U., & Dalal, A.
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2021-12-21
Volume
75
Issue
5
Pages
1194-1203
ISSN
  • 0270-9139
  • 1527-3350
DOI
10.1002/hep.32255
Cited by
85
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review